InspireMD Becomes a Supporting Organization in the Growing Stent for Life Initiative

The Stent for Life Initiative (SFL) Celebrates its First Year Anniversary as the ESC 2010 Congress in Stockholm, Monday August 30th

STOCKHOLM, August 30, 2010 - InspireMD Ltd., a medical device company engaged in the development and
commercialization of MGuard(TM) novel stent systems, is happy to announce
that it has joined the Stent for Life Initiative as a supporting
organization. The Stent for Life Initiative aims to improve the delivery and
patient access to the life saving indications of PCI and thereby reduce the
mortality and morbidity of patients suffering from acute coronary syndromes.

InspireMD, Ltd., is a medical device company, that engages in the
development and commercialization of MGuard, a novel net protective stent
system that is specifically designed to treat thrombus loaded lesions in the
cases of acute coronary syndrome, acute myocardial infarction, or saphenous
vein grafts. "We are delighted to become part of the SFL initiative," stated
Mr. Ofir Paz, CEO at InspireMD. "We are convinced that increasing the use of
primary PCI in STEMI patients is the most important advancement in our field
today and we focus our efforts on providing the best products and solutions
to support this noble initiative."

Stent for Life was initiated one year ago during the European
Association of Percutaneous Cardiovascular Interventions (EAPCI) General
Assembly at the ESC Congress 2009 in Barcelona. The Initiative is a unique
European platform for interventional cardiologists, government
representatives, industry partners, patient groups and patients to work
together and, by shaping the health care systems and medical practices,
ensure that the majority of ST elevation myocardial infarction (STEMI)
patients will have an equal access to the life saving indication of
percutaneous coronary intervention (PCI).

Industry partners, such as InspireMD, sign up because they are
willing to actively support the project goals. This support may include
participating in defining strategy, as well as providing expertise such as
project management, local analysis, patient awareness, promotion, funding and
investment planning.

Join the Stent for Life Declaration signature ceremony at ESC
2010. The Stent for Life Initiative will celebrate its first year anniversary
at ESC 2010 Congress in Stockholm. The ceremony will take place as a
continuation of the EAPCI General Assembly on Monday 30 August, 16:30 -
18:00. Meet the SFL family members to learn about Initiatives' first year
achievements

About MGuard(TM) Coronary

MGuard(TM) presents a novel combination of a coronary stent
merged with an embolic protection. The embolic protection is comprised of an
ultra-thin polymer mesh sleeve that wraps the stent. The MGuard(TM) coronary
stent provides permanent embolic protection, without complicating
deliverability. MGuard(TM) is CE Mark approved. The MGuard(TM) Coronary's
innovative concept has enjoyed an enthusiastic welcome from leading
interventional cardiologists around the world.

About InspireMD

InspireMD is an innovative medical device company focusing on
the development and commercialization of its proprietary stent system
technology, MGuard(TM). The company intends to apply its technology to
develop products used in interventional cardiology and other vascular
procedures. InspireMD's mission is to utilize its proprietary technology to
make its products the industry standard for stents and to provide a superior
solution to the key clinical issues of current stenting: restenosis, embolic
showers, and late thrombosis. In addition to providing embolic protection and
minimizing arterial injury, this promising technology can be an effective and
uniform drug delivery mechanism with the help of the novel micron-level net
for next generation drug eluting stents. InspireMD intends to pursue
applications of this technology both for bare metal and drug eluting stents
in coronary, carotid and peripheral artery procedures.

About Stent for Life:

There is indisputable scientific evidence that myocardial
revascularization in patients with acute forms of coronary artery disease is
life saving; it reduces mortality, rates of non-fatal reinfarction and
stroke, as compared to the previous standard of care (pharmacological
treatment, including thrombolytic therapy for STEMI).

The Stent for Life Initiative is a unique European platform
for interventional cardiologists, government representatives, industry
partners, patient groups and patients to work together and, by shaping the
health care systems and medical practices, ensure that the majority of STEMI
patients will have an equal access to the life saving indication of PCI.

The executive board is: Prof. Petr Widimsky, Co-Chairman; Dr.
Jean Fajadet, Co-Chairman; Dr. William Wijns; Prof. Carlo di Mario; Prof.
Nicolas Danchin; Prof. Steen D. Kristensen; Dr. Zuzana Kaifoszova; Marielle
de la Torre.

The participating organizations are: EAPCI, EuroPCR, the ESC
Working Group on Acute Cardiac Care and the National Cardiology Societies
and/or National Working Groups for Interventional Cardiology (WGIC)

The current member countries are: Egypt, Italy, Romania,
Bulgaria, France, Greece, Serbia, Spain and Turkey.

The industry partners are: Abbott Vascular, Biotronik, Boston
Scientific, Cordis Johnson & Johnson, Eli Lilly,

IHT-Cordynamics, InspireMD, Medtronic, Philips Healthcare,
Terumo Europe and The Medicines Company.

    Contact details:

     www.inspire-md.com

    Jonina Ohayon
    Marketing Director
    jonina@inspire-md.com
    mobile: +972-52-5791120

    www.stentforlife.com

    Zuzana Kaifoszova, M.D., MBA
    Stent for Life Initiative Project Manager, Europe
    kaifosz@gmail.com
    Mobile: +420-724-547-303

Contact details: Jonina Ohayon, Marketing Director, jonina at inspire-md.com, mobile: +972-52-5791120; Zuzana Kaifoszova, M.D., MBA, Stent for Life Initiative Project Manager, Europe, kaifosz at gmail.com, Mobile: +420-724-547-303